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Edited by Hans-Dieter KlenkAbstract HIV-1 integrase (IN) mediates the insertion of viral
cDNA into the cell genome, a vital process for replication. This
step is catalyzed by two separate DNA reaction events, termed
3 0-processing and strand transfer. Here, we show that six inhib-
itors from ﬁve structurally diﬀerent classes of compounds display
a selectivity shift towards preferential strand transfer inhibition
over the 3 0-processing activity of IN when a single serine is
substituted at position C130. Even though IN utilizes the same
active site for both reactions, this ﬁnding suggests a distinct con-
formational dissimilarity in the mechanistic details of each IN
catalytic event.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Integrase (IN) consists of 288 amino acids and contains
three functional domains; the N-terminal domain (residues
1–50), the catalytic core domain (residues 51–212), and the
C-terminal domain (residues 213–288). The protein functions
as a multimer to catalyze the insertion of viral cDNA into
the cell genome to form a stable provirus. This step is catalyzed
by two separate DNA reaction events. The ﬁrst step is termed
3 0-processing. Here a dinucleotide adjacent to a conserved CA
is hydrolytically cleaved oﬀ each terminus of the reverse-tran-
scribed viral DNA. This results in two 3 0 hydroxyl groups that
are used for a subsequent nucleophilic attack in the second
reaction. 3 0-processing occurs within the cytosol. The second
step, strand transfer, is the concerted transesteriﬁcation reac-
tion that results in the insertion of this DNA product within
the host genome [1]. Host cell enzymes presumably execute
the removal of the two unpaired nucleotides on the 5 0 viral
DNA ends, gap ﬁlling, and ligation.
IN reactions can be carried out in vitro using isolated systems
that contain puriﬁed recombinant protein, a DNA oligonucleo-
tide substrate with ends mimicking the U3 or U5 viral DNA ter-
mini, and Mg2+ or Mn2+ as a cofactor [2], as shown in Fig. 1.Abbreviations: HIV-1, human immunodeﬁciency virus type 1; IN, in-
tegrase; WT, wild type; SM, soluble double mutant (F185K/C280S)
integrase protein
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doi:10.1016/j.febslet.2007.02.023Assays utilizing these catalytic activities of IN has enabled
researchers to conduct high throughput screenings for potential
inhibitors, and has uncovered numerous lead compounds for
further development (for review please see Refs. [3–5]). Using
this in vitromethod we present here the activity of six small mol-
ecule IN inhibitors from ﬁve diﬀerent structural classes tested
against wild type (WT) IN, a soluble double mutant (F185K/
C280S) protein (SM), and two other IN mutants containing
an additional substitution at position C130 (Ala and Ser). The
potency of each small molecule inhibitor generally decreased
when tested against the SM versus that of the WT protein, as
previously reported [6]. After the addition of another substitu-
tion at position C130, however, the compounds exhibited a
drastic selectivity shift for inhibition of the strand transfer activ-
ity of IN over 3 0-processing. The selectivity shift was observed
for only the C130S mutant, but not for the C130A protein.
HIV-1 IN participates in multiple functional associations,
including both DNA and protein interactions. An earlier study
has demonstrated that whereas WT IN successfully interacts
with the viral reverse transcriptase enzyme, the C130S mutant
IN protein failed to bind this protein [7]. The inhibition proﬁle
of the C130S mutant IN protein presented here demonstrates
the Cys to Ser substitution at this catalytic core position addi-
tionally alters the interaction of IN with structurally diverse
small molecule inhibitors, and further underscores the impor-
tance of this amino acid for IN structure and function.2. Materials and methods
2.1. Site directed mutagenesis
Site directed mutagenesis was conducted on the pET-15b-IN plas-
mid, a generous gift from Dr. Robert Craigie, Laboratory of Molecu-
lar Biology, NIDDK, NIH, Bethesda, MD. The plasmid contains full
length IN (F185K/C280S) fused to a 6-residue N-terminal histidine tag
downstream from a T7 promoter. A Quickchange site-directed muta-
genesis kit (Stratagene) was employed to make the point mutations
according to the manufacturer’s instructions, and the primers used
to introduce the amino acid substitutions (Ala and Ser) have been de-
scribed previously [8]. Nucleotide replacements were conﬁrmed by
sequencing at the USC/Norris Comprehensive Cancer Center Micro-
chemical Core Facility (University of Southern California).
2.2. Expression and puriﬁcation of recombinant HIV-1 integrase
The IN plasmid was expressed in Escherichia coli BL21(De3) PLYS
S expression strain (Invitrogen) after induction by IPTG (1 mM) at an
absorbance of 0.6–0.8 optical density at 595 nm. The culture was al-
lowed to grow for an additional 3–4 h at 37 C. This was followed
by centrifugation of the cells at 3000 rpm in a bucket rotor centrifuge
(Beckman) for 20 min. Cell lysis, Ni-aﬃnity chromatography puriﬁca-
tion and dialysis were performed as detailed in [8].blished by Elsevier B.V. All rights reserved.
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Fig. 1. Schematic of IN activity in vitro: a 21-mer oligonucleotide
corresponding to the U5 LTR 5 0-end-labeled with 32P is reacted with
puriﬁed IN. The ﬁrst step, 3 0-processing involves nucleolytic cleavage
of two bases from the 3 0-end resulting in a 19-mer oligonucleotide. The
3 0-ends are subsequently covalently joined at several sites to another
identical oligonucleotide that serves as the target DNA. This reaction
is known as strand transfer, and the products formed migrate slower
than the original substrate on a polyacrylamide gel.
1152 L.Q. Al-Mawsawi et al. / FEBS Letters 581 (2007) 1151–11562.3. Oligonucleotide substrates and IN inhibition assays
Oligonucleotide substrates mimicking the HIV-1 U5 LTR DNA ter-
mini, a 21-mer top strand (5 0-GTGTGGAAAATCTCTAGCAGT-3 0),
and a 21-mer bottom strand (5 0-ACTGCTAGAGATTTTCCACAC-
3 0), were purchased from USC/Norris Comprehensive Cancer Center
Microchemical Core Facility (University of Southern California) and
puriﬁed by UV shadowing on polyacrylamide gel. In order to quanti-
tate both DNA reaction events, the 21-mer top oligonucleotide was 5 0-
end-labeled using T4 polynucleotide kinase (Epicenter, Madison, WI)
and c-[32P]ATP (MP Biomedicals, Irvine, CA). Afterwards the kinase
was heat inactivated, and the 21-mer bottom oligonucleotide was
added in 1.5 M excess. The sample was then heated to 95 C, cooled
slowly, and subsequently passed through a G-25 Sephadex spin col-
umn (USA Scientiﬁc) to remove any unincorporated material from
the annealed double-stranded oligonucleotide. Compounds 3 and 4
were purchased from commercial provider ChemDiv Inc.
IN inhibition assays for wild type, soluble mutant, C130A, and
C130S followed the same general procedure. To determine the degree
of inhibition on both 3 0-processing and strand transfer, puriﬁed IN en-
zyme (ﬁnal concentration: 200 nM) was pre-incubated with inhibitor
(dissolved in DMSO; stored at 20 C) in a reaction buﬀer [7.5 mM
MnCl2, 0.1 mg/mL bovine serum albumin, 10 mM b-mercaptoethanol,
and 25 mMMOPS, pH 7.2] for 30 min. at 30 C. This was followed by
the addition of 20 nM of the 5 0-end 32P-labeled linear double stranded
oligonucleotide, and incubation was continued for an additional 1 h at
the same temperature. Upon completion the sample reactions were
quenched by adding half the total volume (8 lL) of loading dye
(98% deionized formamide, 10 mM EDTA, 0.025% xylene cyanol,
and 0.025% bromophenol blue). A sample aliquot was electrophoresed
on a denaturing 20% polyacrylamide gel (0.09 M Tris–borate, pH 8.3,
2 mM EDTA, 20% acrylamide, and 8 M urea).
Gels were vacuum dried, exposed in a PhosphorImager cassette,
analyzed using a Typhoon 8610 Variable Mode Imager (Amersham
Biosciences), and quantiﬁed using ImageQuant 5.2. Percent inhibition
(%I) was calculated using the following equation:
%I ¼ 100 ½1 ðD CÞ=ðN  CÞ
where C, N, and D are the fractions of 21-mer substrate converted to
19-mer (3 0-processing product) or strand transfer products for DNA
alone, DNA plus IN, and IN plus drug, respectively. IC50 values were
determined by plotting the logarithm of drug concentration versus the
calculated percent inhibition to obtain the concentration that produced
50% inhibition.3. Results
In a previous inhibitor binding study we constructed both
C130A and C130S mutants in the context of the SM IN pro-
tein [8], and their relative catalytic activities are discussed here.The SM protein proved to be as catalytically active as WT, as
described earlier [9]. Upon testing various structurally diverse
inhibitors on these mutants a pattern of inhibitory selectivity
emerged for the C130S protein. Regardless of inhibitor struc-
ture or proposed mechanism of action, when tested on
C130S the compound exhibited greater speciﬁcity towards
inhibition of the strand transfer reaction of IN over 3 0-process-
ing. This selectivity shift was generated by an increased suscep-
tibility towards strand transfer inhibition in combination with
an apparent resistance towards 3 0-processing inhibition by the
C130S enzyme.
The IN inhibitors used in this study, and their calculated
IC50 values against each IN enzyme are shown in Table 1.
The potency of each inhibitor generally decreased when tested
against SM versus that of WT, consistent with earlier studies
[6]. Both C130 mutants were constructed in the context of
the SM. All inhibitor IC50 values obtained against C130A
and C130S will be discussed in comparison to the correspond-
ing IC50 values acquired against SM, since these values repre-
sent a more accurate baseline as compared to those calculated
after compound testing with WT. Inhibitor IC50 values ob-
tained after WT testing are given, however, to provide a more
balanced perspective. Additionally, compounds 3 and 4 are
original IN inhibitors that were commercially synthesized
and initially identiﬁed through compound screening. These
IN inhibitors are introduced in this study, and as such the pre-
sentation and discussion of their activity against WT is war-
ranted. Compound 1 is a derivative of a previously described
dihydroxyindole-2-carboxylic acid class of IN inhibitors [10].
This class of compounds was designed as conformationally
constrained analogues of caﬀeic acid phenethyl ester, a known
IN inhibitor. When tested against C130A, 1 showed a slight in-
crease in potency as compared to SM. When tested against
C130S, on the other hand, a seven-fold increase in potency
was observed for 3 0-processing inhibition, whereas close to a
60-fold increase in potency was observed for strand transfer
inhibition. Interestingly, during initial characterization of 1 a
similar increase in strand transfer potency (slightly greater
than 10-fold) was documented for a C65S mutant of IN over
that of SM [10], suggesting a common cysteine–serine depen-
dant mechanism for the observed increase in strand transfer
selectivity for this compound. Inhibitor 2 was discovered
through a database search using a four-feature 3D pharmaco-
phore model as a query [11]. The common feature pharmaco-
phore model was designed using the ﬁrst IN inhibitor clinical
candidate S-1360 (5 in this study) and three other b-diketo acid
analogues. 2 exhibited a three-fold potency reduction for 3-
processing inhibition, and about a two-fold potency increase
for strand transfer inhibition when tested against C130A.
The selectivity shift was more pronounced when tested against
C130S. Against the serine mutant 2 displayed close to a six-
fold potency reduction for 3 0-processing inhibition, and a
two and a half times potency increase against the strand trans-
fer activity. Compounds 3 and 4 have not previously been
characterized for anti-IN activity. Each contain an aromatic
catechol attached to a heterocyclic aromatic moiety. Both
compounds exhibit modest anti-IN activity, with slight speci-
ﬁcity for strand transfer inhibition. For 3, WT IC50 values
are 44 ± 5 and 23 ± 7, whereas for 4 WT IC50 values are
66 ± 24 and 16 ± 7, in lM, each for 3 0-processing and strand
transfer, respectively. Compound 3 moderately lost some po-
tency when tested against SM. The activity of 3 was relatively
Table 1
Inhibition activitiesa against integrase proteins by compounds 1–6
Compound WT SM C130A C130S
N
H
OH
OH O
N
N
O
N
H
OH
OH
1
3 0-Processing 2 ± 1 7 ± 1 5 ± 3 1 ± < 1
Strand transfer 2 ± 1 7 ± 2 4 ± 1 0.12 ± 0.02
N N
O
O
O
O
O
OH OH
OH
O OH
O
2
3 0-Processing 21 ± 1 31 ± 6 102 ± 26 168 ± 24
Strand transfer 12 ± 3 41 ± 11 26 ± 10 13 ± 1
N
N
S
OH
S
O
OH
OH
3
3 0-Processing 44 ± 5 54 ± 4 53 ± 3 153 ± 6
Strand transfer 23 ± 7 41 ± 8 36 ± 7 6 ± 2
N
N
N
OH
S
O
OH
OH
4
3 0-Processing 66 ± 24 67 ± 10 143 ± 31 277 ± 15
Strand transfer 16 ± 7 60 ± 14 53 ± 3 8 ± 4
F
O O
OH
NH
N
N
5 (S-1360)
3 0-Processing 11 ± 2 36 ± 7 45 ± 6 168 ± 11
Strand transfer 0.6 ± 0.1 2 ± 1 4 ± 2 2 ± 1
OH
N
H
O
N
H
O
OH
6
3 0-Processing 3 ± 1 9 ± 2 2 ± 1 53 ± 9
Strand transfer 1 ± < 1 9 ± 4 3 ± 2 0.4 ± 0.08
WT – wild type; SM – soluble double mutant (F185K/C280S); C130A and C130S made in context of SM.
aIC50 values given in lM.
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three-fold reduction in potency for 3 0-processing inhibition
and close to a 7-fold potency increase in strand transfer inhibi-
tion for 3 against C130S. When 4 was tested against SM, a de-
crease in potency was only observed for strand transfer
inhibition, while all other compounds exhibited a reduction
in potency for both SM catalytic activities in comparison to
WT. Compound 4 exhibited a two-fold potency reduction
for 3 0-processing inhibition when tested against C130A,
whereas strand transfer potency remained the same. Whentested against C130S 4 was over four and a half times less eﬀec-
tive for 3 0-processing inhibition, and exhibited over a 7-fold
potency increase in strand transfer inhibition, similar to 3.
Compound 5, or S-1360, is a strand transfer speciﬁc IN inhib-
itor ﬁrst discovered by Shionogi & Co., and recently failed clin-
ical trials [12–14]. S-1360 is a derivative of the b-diketo acid
class of compounds, which have emerged as one of the most
therapeutically promising class of IN inhibitors. The fact that
S-1360 represents a class of IN inhibitors that are already
strand transfer speciﬁc was the major reason behind our
Fig. 2. C130S exhibits increased susceptibility for strand transfer inhibition in combination with an increased resistance towards 3 0-processing
inhibition. Inhibition by compound 6 on WT (A), SM (B), C130A (C), C130S (D and E). Compound 6 decreases in micromolar concentrations. STP
refers to strand transfer products.
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when tested against C130A. Interestingly, when tested against
C130S a greater than ﬁve-fold potency reduction was observed
for 3 0-processing inhibition, but strand transfer activity of the
compound was un-altered. Compound 6 is an eﬀective bis-
hydrazide IN inhibitor discovered as the principal component
in a compound mixture showing anti-IN activity [15]. Com-
pound 6 exhibited greater than a three-fold potency increase
for 3 0-processing inhibition when tested against C130A. The
activity of the compound against strand transfer inhibition
was largely unchanged against the alanine mutant. When
tested against C130S, however, 6 displayed the most extreme
selectivity shift of any compound tested. The molecule exhib-
ited over a six-fold potency reduction for 3 0-processing inhibi-
tion combined with greater than a 12-fold potency increase for
strand transfer inhibition when tested against the serine mu-
tant. A representative gel depicting the activity of compound
6 against each IN protein is shown in Fig. 2, panels A–E.
To better illustrate the selectivity shift of each compound to-
wards preferential strand transfer inhibition we calculated the
selectivity index of each inhibitor when tested against SM,
C130A, and C130S. The results are shown in Fig. 3. Minor
selectivity was observed for inhibitors 1–4 and 6 when tested
against WT, however none of these compounds displayed
selectivity when tested against SM. The strand transfer speciﬁc
diketo acid derivative 5 was eighteen times more selective forCompound
0
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1 2 3 4 5 6
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Fig. 3. A drastic selectivity shift towards preferential strand transfer
inhibition is observed for all compounds tested against C130S. The
selectivity index (SI) was calculated by dividing the 3 0-processing IC50
value by the strand transfer IC50value.this IN catalytic activity when tested against both WT and
SM. When tested against C130A compounds 2–4 became
slightly more strand transfer speciﬁc, whereas compounds 1
and 6 remained un-selective when tested against this enzyme.
Compound 5 exhibited a decrease in strand transfer selectivity
when tested against C130A. All inhibitors displayed a selectiv-
ity shift toward preferential strand transfer inhibition when
tested against C130S. The most dramatic selectivity shift was
observed for 6. This compound was not selective for either
IN activity when tested against SM or C130A, but was 133-
times more selective for strand transfer inhibition when tested
against C130S.4. Discussion
Previously, we identiﬁed the peptide region surrounding
C130 (128-136) as the binding site of a set of coumarin-con-
taining IN inhibitors [8]. These inhibitors were found to inter-
act speciﬁcally with the peptide backbone at positions A133
and G134, and potentially interrupt multimer formation.
Introducing a serine substitution at C130 and non-conserva-
tive substitutions at W132 were each found to create structural
alterations to this peptide region, thereby disrupting the con-
formation of the coumarin binding site and possibly multi-
meric formation. In this work we observe altered inhibition
proﬁles towards preferential strand transfer inhibition in a ser-
ies of structurally diverse small molecule inhibitors tested
against C130S. The selectivity shift appears to be independent
on the type of inhibitory agent. Previous results from our
group observed a similar bias towards strand transfer inhibi-
tion when a set of inhibitory peptides (derived from the viral
enzyme reverse transcriptase) were tested [16]. These results
suggest the introduction of a serine substitution at C130 may
create a signiﬁcant structural disruption to IN, and is not lim-
ited to the coumarin binding site surrounding C130 at the di-
meric interface of IN as previously thought. Fig. 4 shows a
modiﬁed version of the IN catalytic core domain dimer
(PDB 1BIS) [17] highlighting the position of C130 relative to
the enzyme active site. In all IN catalytic core crystal structures
analyzed the sidechain of C130 adopted a buried conformation
providing further support that the structural impact of certain
substitutions at this position may not be limited to the resi-
due’s local protein environment. Structural perturbations
caused by C130 substitutions have been documented and re-
ported by other studies. For example, a glycine substitution
Fig. 4. The sidechain of C130 adopts a buried conformation in the IN
catalytic core domain dimer structure (PDB 1BIS). Chain A (blue) and
chain B (green) of IN dimer shown in surface representation. IN
residue C130 (yellow) and active site residues D64, D116, and E152
(red) shown in stick representation.
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formation of IN, and reduced the viral infectivity [18]. HIV-1
viruses containing mutant C130S IN protein were also found
to be non-infectious in CD4+-T-cell lines. Furthermore, lysate
from these infected CD4+-T-cells did not contain early DNA
reverse transcripts [7]. Coimmunoprecipitation studies re-
vealed that WT IN interacted with reverse transcriptase (RT)
via its C-terminal domain, but the interaction was abolished
in C130S mutant IN proteins. The non-infectivity of viruses
harboring the C130S IN protein was attributed to a viral fail-
ure to initiate the reverse transcription process [7]. This pro-
vided evidence that the IN–RT interaction is functionally
critical for viral replication, and the C130S substitution indi-
rectly abolished the contacts between the IN C-terminal do-
main and RT [7]. Another substitution at this position,
C130A, exhibited wild-type replication kinetics [19]. It was
proposed that C130 is not critical for HIV-1 replication di-
rectly, and that the infectivity results of other C130 mutations
were due to structural perturbations. It is currently not clear
whether C130 is involved in inter-molecular disulﬁde bridges
during multimerization. Previously, a study determined that
two C280 residues from independent monomers can form
disulﬁde bridges in vitro and in vivo, but this covalent linkage
was not essential for viral replication [20]. The authors were
unable to determine whether C130 is involved in disulﬁde link-
ages during IN dimerization. This was due to the instability of
the full length C130S mutant in the eukaryotic expression sys-
tem used.
In summary, we have shown that six IN inhibitors from ﬁve
diﬀerent classes all exhibit selective inhibition of the strand
transfer process over 3 0-processing when tested against the
IN mutant C130S. The preferential strand transfer selectivity
shift ranged from eight-fold for compound 1 to over 130-fold
for compound 6. Consistent with previous data, we believe the
serine substitution at position C130 creates signiﬁcant struc-
tural alterations to IN highlighting the importance of this res-
idue for IN structure, indirectly for enzymatic function, RT
interaction and viral replication. Although IN utilizes the same
active site for both 3 0-processing and strand transfer, the factthat substituting a serine residue for cysteine at position 130
creates a bias for strand transfer inhibition over 3 0-processing
also suggests a distinct conformational dissimilarity in the
mechanistic details of these two reactions. This is the ﬁrst re-
port demonstrating that a single amino acid substitution in
the IN catalytic core creates a dramatic shift in inhibitor selec-
tivity.
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